Dublin, June 29, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Primary Myelofibrosis Forecast in 8 Major Markets 2016-2026" report to their offering.

Primary Myelofibrosis (PMF), also known as myelofibrosis, myeloid metaplasia or chronic idiopathic myelofibrosis, is part of the collection of diseases known as myeloproliferative neoplasms (MPNs). PMF is a chronic blood cancer that affects the haematopoietic system, causing progressive fibrosis of the bone marrow and impairs the ability of new blood cell production. Eventually, the bone marrow is unable to produce blood cells, and the spleen and liver take over the function causing abdominal swelling and discomfort.

This report provides the current prevalent population for PMF across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight, several of the main symptoms and co-morbidities of PMF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PMF include:

- Portal hypertension
- Thrombosis
- Anaemia
- Gout
- Extramedullary haematopoiesis
- Leukocytosis
- Splenomegaly
- Acute myeloid leukaemia

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key Co-morbid Conditions/Features Associated with the Disease

8. Methodology for Quantification of Patient Numbers

9. Top-Line Prevalence for Primary Myelofibrosis

10. Features of PMF Patients
- Staging and Scores of PMF
- Cell Counts in PMF Patients
- Associated Conditions of PMF
- JAK2 Mutation in PMF Patients

11. Abbreviations used in the Report

12. Patient-Based Offering

13. Online Pricing Data and Platforms

14. References

15. Appendix

For more information visit http://www.researchandmarkets.com/research/84qqq9/primary

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Pharmaceuticals

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.